• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.

作者信息

Costa Luciano J, Medvedova Eva, Dhakal Binod, Dholaria Bhagirathbhai R, Godby Kelly N, Bal Susan, Ravi Gayathri, Giri Smith, Chhabra Saurabh, Silbermann Rebecca, Callander Natalie S

机构信息

Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.

Division of Hematology/Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

出版信息

Blood Cancer J. 2025 Feb 5;15(1):13. doi: 10.1038/s41408-025-01219-7.

DOI:10.1038/s41408-025-01219-7
PMID:39910064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11799218/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ca/11799218/5b0e2d6f8e9d/41408_2025_1219_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ca/11799218/5b0e2d6f8e9d/41408_2025_1219_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ca/11799218/5b0e2d6f8e9d/41408_2025_1219_Fig1_HTML.jpg

相似文献

1
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.四联疗法治疗新诊断多发性骨髓瘤中孤立性微小残留病进展的意义
Blood Cancer J. 2025 Feb 5;15(1):13. doi: 10.1038/s41408-025-01219-7.
2
Case series: MRD negativity assessment using C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma.病例系列：在新诊断的多发性骨髓瘤中，使用C-醋酸盐PET评估微小残留病阴性，并采用每3周一次基于达雷妥尤单抗的四联诱导方案。
Ther Adv Hematol. 2021 Sep 30;12:20406207211030369. doi: 10.1177/20406207211030369. eCollection 2021.
3
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.四联疗法治疗多发性骨髓瘤中，采用下一代测序技术量化自体造血细胞移植对疾病负担的影响。
Am J Hematol. 2022 Sep;97(9):1170-1177. doi: 10.1002/ajh.26640. Epub 2022 Jul 6.
4
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.新诊断多发性骨髓瘤（MASTER）中基于微小残留病灶反应的适应性治疗：多中心、单臂、2 期试验的最终报告。
Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27.
5
Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis.四联疗法治疗新诊断的适合移植的多发性骨髓瘤的疗效和安全性：一项系统评价和荟萃分析
Cancer Rep (Hoboken). 2025 Apr;8(4):e70171. doi: 10.1002/cnr2.70171.
6
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.依洛尤单抗联合每周卡非佐米、来那度胺和地塞米松治疗无移植意向的初诊多发性骨髓瘤患者：一项基于可测量残留病灶的 2 期适应性研究。
JAMA Oncol. 2022 Sep 1;8(9):1278-1286. doi: 10.1001/jamaoncol.2022.2424.
7
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.四联方案治疗初诊多发性骨髓瘤患者的系统评价和荟萃分析。
Blood Adv. 2024 Dec 10;8(23):5993-6002. doi: 10.1182/bloodadvances.2024014139.
8
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.新型诱导治疗时代新诊断多发性骨髓瘤患者自体干细胞移植后深化反应。
Transplant Cell Ther. 2022 Nov;28(11):760.e1-760.e5. doi: 10.1016/j.jtct.2022.07.030. Epub 2022 Aug 5.
9
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.《基于CD38单克隆抗体的四联疗法在新诊断多发性骨髓瘤临床实践中的共识指南与建议：泛太平洋多发性骨髓瘤工作组》
Clin Hematol Int. 2025 Apr 11;7(2):1-19. doi: 10.46989/001c.133682. eCollection 2025.
10
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.抗CD38单克隆抗体疗法与标准疗法在新诊断的多发性骨髓瘤患者中的疗效和安全性：一项系统评价和荟萃分析
Ther Adv Hematol. 2025 Jan 27;16:20406207251314289. doi: 10.1177/20406207251314289. eCollection 2025.

引用本文的文献

1
Novelties on Multiple Myeloma from the Main 2024 Hematology Conferences.2024年主要血液学会议上多发性骨髓瘤的新进展。
Mediterr J Hematol Infect Dis. 2025 Mar 1;17(1):e2025027. doi: 10.4084/MJHID.2025.027. eCollection 2025.

本文引用的文献

1
MRD accelerating myeloma drug development.
Blood. 2024 Jul 25;144(4):345-347. doi: 10.1182/blood.2024025421.
2
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
3
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.证据荟萃分析：评估微小残留病灶作为多发性骨髓瘤的中间临床终点。
Blood. 2024 Jul 25;144(4):359-367. doi: 10.1182/blood.2024024371.
4
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
5
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.多发性骨髓瘤患者不可持续的可测量残留疾病阴性的预测因素。
Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.
6
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.适合移植的多发性骨髓瘤患者中不可持续的可测量残留疾病阴性的预测因素。
Blood. 2024 Feb 15;143(7):597-603. doi: 10.1182/blood.2023022083.
7
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.新诊断多发性骨髓瘤（MASTER）中基于微小残留病灶反应的适应性治疗：多中心、单臂、2 期试验的最终报告。
Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27.
8
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤患者（GRIFFIN）：一项开放标签、随机、2 期试验的最终分析。
Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11.
9
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.对 clonoSEQ 检测方法在急性淋巴细胞白血病、慢性淋巴细胞白血病和多发性骨髓瘤中建立可测量（最小）残留病的分析评估。
BMC Cancer. 2020 Jun 30;20(1):612. doi: 10.1186/s12885-020-07077-9.
10
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.